Christin L. Melton


Targeted Therapies End the Dry Spell in AML Drug Development

Targeted agents are routinely used to treat many cancers and have improved outcomes for patients with solid tumors and hematological malignancies alike. Recently, targeted therapies made their way into the armamentarium for acute myeloid leukemia, representing the first therapeutic advances for AML in decades.

Christin L. Melton, ELS


Recent Studies Point to a Greater Role for PARP Inhibitors in Solid Tumors

The early development of PARP inhibitors in 2003 focused on their use in combination with cytotoxic chemotherapy agents, but this was eventually abandoned because of excess toxicity.

Christin Melton


Epidemic in Sex-Related Oral Cancer Highlights Need for Guidelines

Over the past few decades, the annual incidence of OPSCC has increased sharply in several countries, including in the United States.

Christin Melton, ELS


Study Validates Noninvasive Urinary Cell-Free DNA Assay for Urothelial Bladder Cancer

A recent study has shown that extracting cell-free DNA from urine is a highly effective technique for analyzing the genetic profile of urothelial bladder cancers.

Christin Melton, ELS, CMPP


Whole-Genome Sequencing Identifies New Targets in Pancreatic Cancer

A research team led by investigators at the University of Texas Southwestern Medical Center in Dallas has published a study in Nature Communications identifying several new genetic mutations in pancreatic ductal adenocarcinoma.

Christina Baik, MD, MPH


Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer

Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.

Christina Izzo


Improving Quality of Life in Cervical Cancer Survivors

A new study has found that a psychosocial telephone counseling intervention helps improve mood and quality of life in cervical cancer survivors.

Christina M. Annunziata, MD, PhD


A Study of Olaparib and Cediranib in Ovarian Cancer

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Christina T. Logudice


New Device Treats Nonmelanoma Skin Cancer Noninvasively

According to the Skin Cancer Foundation, more than 3.5 million cases of nonmelanoma skin cancers (NMSCs) are treated in the United States annually, making it the most commonly encountered malignancy.

Christina T. Loguidice


Study Suggests Panurothelial Carcinoma Warrants More Aggressive Surgical Treatment

A study published in Scientific Reports by researchers from China indicates panurothelial carcinoma (panUCC) has a high risk of recurring, progressing, and disseminating after conservative surgery, leading to poor outcomes.

Christine Lehmann


Quantifying the Benefits of Precision Oncology

Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.

Christine Lehmann, MA


Immunotherapy and TKI Combinations Are Emerging as Standard of Care in Advanced RCC

The results of several studies presented at the 2019 Genitourinary Cancers Symposium confirmed that the combination of PD-1/PD-L1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway was superior to VEGF inhibitors alone in patients with clear cell renal cell carcinoma, which accounts for about 70% of patients with kidney cancer.

Christine M. Lovly, MD, PhD


Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.

Christine Tran, MS


The Emerging Role of Mobile Health in Oncology

This article offers an overview of mobile health technology as it relates to a participatory care model and shared decision making.

Christoph Roellig, MD


Dr. Roellig on FLT3 ITD/NPM1 Mutation Status for Patients With AML

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Christophe Mariette, MD, PhD


The Impact of Age, Comorbidity on Postoperative Outcomes in Esophageal and Gastric Cancer

Christophe Mariette, MD, PhD, surgical oncologist and professor of surgery, University Hospital of Lille in France, discusses a nationwide study investigating the impact of age and comorbidities on postoperative mortality after esophageal and gastric cancer surgery.

Christopher E. Barbieri, MD, PhD


The Role of PARP Inhibitors in Prostate Cancer

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the role of PARP inhibitors in castration-resistant prostate cancer.

Christopher Filson, MD


MR-US Fusion Biopsy for Detecting High-Grade Prostate Cancer

Christopher Filson, MD, urology, UCLA Medical Center, discusses a study that used a MR-US fusion biopsy in 1000 men as a method to diagnose high-grade prostate cancer.

Christopher Heery, MD


The Potential Benefits of Combination Therapy for Patients with GI Cancers

Christopher Heery, MD, medical oncologist, National Cancer Institute, discusses the potential underlying benefits of combination therapy in the treatment of patients with gastrointestinal (GI) cancers.

Christopher J. Hoimes, DO


Addressing an Unmet Medical Need in Urothelial Carcinoma

Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.

Christopher R. Cogle, MD


Expert Explains the Greatest Challenge in Treating Patients With MDS and AML

Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.

Christopher R. Flowers, MD


Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients

Christopher Sweeney, MBBS


Expert Discusses Safety Profile from the ENZAMET Trial

Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events associated with adding enzalutamide or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET trial.<br /> &nbsp;

Christopher Twelves, MD


Dr. Christopher Twelves on the Rising Issue of Metastatic Breast Cancer

Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed.

Christopher Y. Park, MD


Biggest Challenges in MDS

Christopher Y. Park, MD, PhD, hematopathologist, Memorial Sloan Kettering Cancer Center, discusses some of the biggest challenges in myelodysplastic syndromes (MDS).

Chung-Han Lee, MD, PhD


Moving Forward With Adjuvant Therapies in RCC

Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.

Claire Harrison, MD


Dr. Claire Harrison on the Benefits of Ruxolitinib in Advanced Myelofibrosis

Claire Harrison, MD, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.